Technical Analysis for SBBP - Strongbridge Biopharma plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Historical SBBP trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | -2.02% | |
| Oversold Stochastic | Weakness | -2.02% | |
| Stochastic Buy Signal | Bullish | -2.81% | |
| Narrow Range Bar | Range Contraction | -2.81% | |
| NR7 | Range Contraction | -2.81% | |
| NR7-2 | Range Contraction | -2.81% | |
| Wide Bands | Range Expansion | -2.81% | |
| Oversold Stochastic | Weakness | -2.81% | |
| Narrow Range Bar | Range Contraction | -2.81% | |
| NR7 | Range Contraction | -2.81% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Down 3% | about 2 hours ago |
| Down 2 % | about 3 hours ago |
| Down 1% | about 3 hours ago |
| Fell Below Previous Day's Low | about 3 hours ago |
| Down 2 % | 1 day ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 10/29/2020
Strongbridge Biopharma plc, a biopharmaceutical company, through its subsidiary, Cortendo AB (publ), develops, acquires, and commercializes product candidates that target rare diseases. The company's lead product candidate, COR-003 (levoketoconazole), is a cortisol inhibitor that is in the Phase 3 trial for the treatment of endogenous Cushing's syndrome. It also has two product candidates, COR-004 and COR-005 in Phase 2 clinical development to treat acromegaly. In addition, it is developing BP-2001, a pre-clinical product candidate for the treatment of diabetes. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is based in Trevose, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Development Organ Systems Diabetes Chemical Compounds Rare Diseases Chloroarenes Treatment Of Diabetes Acromegaly Cushing's Syndrome Adrenal Gland Disorders Piperazines Cortisol Endogenous Cushing's Syndrome
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Development Organ Systems Diabetes Chemical Compounds Rare Diseases Chloroarenes Treatment Of Diabetes Acromegaly Cushing's Syndrome Adrenal Gland Disorders Piperazines Cortisol Endogenous Cushing's Syndrome
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.63 |
| 52 Week Low | 1.87 |
| Average Volume | 1,227,976 |
| 200-Day Moving Average | 2.92 |
| 50-Day Moving Average | 3.02 |
| 20-Day Moving Average | 2.77 |
| 10-Day Moving Average | 2.64 |
| Average True Range | 0.20 |
| ADX | 15.99 |
| +DI | 20.01 |
| -DI | 19.20 |
| Chandelier Exit (Long, 3 ATRs ) | 3.22 |
| Chandelier Exit (Short, 3 ATRs ) | 3.03 |
| Upper Bollinger Band | 3.28 |
| Lower Bollinger Band | 2.27 |
| Percent B (%b) | 0.2 |
| BandWidth | 36.55 |
| MACD Line | -0.14 |
| MACD Signal Line | -0.11 |
| MACD Histogram | -0.0275 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.62 | ||||
| Resistance 3 (R3) | 2.63 | 2.58 | 2.60 | ||
| Resistance 2 (R2) | 2.58 | 2.55 | 2.58 | 2.59 | |
| Resistance 1 (R1) | 2.53 | 2.52 | 2.51 | 2.52 | 2.58 |
| Pivot Point | 2.48 | 2.48 | 2.47 | 2.48 | 2.48 |
| Support 1 (S1) | 2.43 | 2.45 | 2.41 | 2.42 | 2.36 |
| Support 2 (S2) | 2.38 | 2.42 | 2.38 | 2.35 | |
| Support 3 (S3) | 2.33 | 2.38 | 2.35 | ||
| Support 4 (S4) | 2.32 |
